Lifecore Biomedical, Inc.

NasdaqGS:LFCR Stock Report

Market Cap: US$266.6m

Lifecore Biomedical Future Growth

Future criteria checks 0/6

Lifecore Biomedical's earnings are forecast to decline at 40.1% per annum while its annual revenue is expected to grow at 9.1% per year. EPS is expected to decline by 38.4% per annum.

Key information

-40.1%

Earnings growth rate

-38.4%

EPS growth rate

Life Sciences earnings growth17.8%
Revenue growth rate9.1%
Future return on equityn/a
Analyst coverage

Low

Last updated25 Nov 2024

Recent future growth updates

Recent updates

Lifecore Biomedical: An Interesting CDMO Pure Play

Dec 01

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Soars 36% But It's A Story Of Risk Vs Reward

Nov 26
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Soars 36% But It's A Story Of Risk Vs Reward

Lifecore Biomedical: Finally A 'Pure Play' CDMO Business

Nov 12

Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty

Jun 24

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Apr 20

Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?

Jun 30
Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?

Landec Non-GAAP EPS of -$0.32, revenue of $43.35M

Oct 06

Landec receives Nasdaq's notification on delayed annual report filing

Sep 09

Laughing Water Capital - Landec Corp. : A High Quality CDMO

Jul 27

Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt

Jun 24
Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Apr 08
Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

Mar 21
Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

Earnings and Revenue Growth Forecasts

NasdaqGS:LFCR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
5/31/2027155-220N/A3
5/31/2026139-24-10N/A3
5/31/2025129-31-21N/A3
8/25/20241286-97N/A
5/26/20241289-180N/A
2/25/2024122-21-34-11N/A
11/26/2023112-47-45-21N/A
8/27/2023104-70-48-25N/A
5/28/2023103-64-39-17N/A
2/26/202393-31-41-16N/A
11/27/2022104-27-46-22N/A
8/28/202293-15-50-25N/A
5/29/2022111-15-53-23N/A
2/27/2022135-12-49-18N/A
11/28/2021142-7-37-8N/A
8/29/202178-6-28-1N/A
5/30/2021101-23-916N/A
2/28/2021283-24-18-2N/A
11/29/2020391-34-216N/A
8/30/2020587-44-165N/A
5/31/2020160-22-44-17N/A
2/23/2020587-23-39-6N/A
11/24/2019590-10-46-4N/A
8/25/2019572-3-328N/A
5/26/20195582-2916N/A
2/24/20195468-2917N/A
11/25/201853523-2418N/A
8/26/201853324-2419N/A
5/27/201852426N/A20N/A
2/25/201844821N/A27N/A
11/26/20174408N/A31N/A
8/27/20174539N/A27N/A
5/28/201747010N/A30N/A
2/26/201754013N/A39N/A
11/27/2016534-12N/A25N/A
8/28/2016538-11N/A30N/A
5/29/2016477-12N/A21N/A
2/28/2016540-12N/A19N/A
11/29/201554913N/A25N/A
8/30/201554114N/A20N/A
5/31/201553914N/A27N/A
3/1/201552614N/A21N/A
11/30/201451417N/A20N/A
8/31/201450117N/A20N/A
5/25/201447719N/A21N/A
2/23/201446319N/A22N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LFCR's earnings are forecast to decline over the next 3 years (-40.1% per year).

Earnings vs Market: LFCR's earnings are forecast to decline over the next 3 years (-40.1% per year).

High Growth Earnings: LFCR's earnings are forecast to decline over the next 3 years.

Revenue vs Market: LFCR's revenue (9.1% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: LFCR's revenue (9.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LFCR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 23:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/08/25
Annual Earnings2024/05/26

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lifecore Biomedical, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander ParisBarrington Research Associates, Inc.
Michael PetuskyBarrington Research Associates, Inc.
Matthew HewittCraig-Hallum Capital Group LLC